Drug intelligence / Profile preview

donepezil + leuprolide

Development stage
Unknown
Lead developer
Voyager Therapeutics
Modality
Small Molecules, Peptides
Administration
Oral, Intramuscular, Subcutaneous
01

Overview

Donepezil + leuprolide is an investigational combination therapy for Alzheimer's disease, particularly studied in women. Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain by inhibiting its breakdown, thereby improving cognitive function and slowing symptom progression in Alzheimer's disease. Leuprolide is a gonadotropin-releasing hormone (GnRH) receptor agonist that ultimately suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), reducing sex steroid production. In the context of Alzheimer's disease, leuprolide may exert neuroprotective effects by modulating LH levels, which are implicated in amyloid production and neuronal cell cycle re-entry leading to neurodegeneration. Clinical studies have shown that this combination can halt or slow cognitive decline more effectively than donepezil alone in certain subgroups of women with mild to moderate Alzheimer’s disease[2][5][6].

02

Targets

AcetylcholinesteraseGnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on donepezil + leuprolide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on donepezil + leuprolide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call